SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Eagle Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 9, 2024 - (NASDAQ: EGRX)

NEW YORK, Jan. 26, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Eagle Pharmaceuticals, Inc..

Shareholders who purchased shares of EGRX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

CONTACT US HERE:

https://securitiesclasslaw.com/securities/eagle-pharmaceuticals-inc-loss-submission-form/?id=64783&from=4

CLASS PERIOD: August 8, 2023 to November 28, 2023

ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) that the Company was experiencing slower-thananticipated pull-though from a wholesale customer predominantly due to expiry of inventory; (2) that, as a result, the Company had overstated its revenue; (3) that the Company did not have effective internal controls and procedures over financial reporting as to sales of PEMFEXY, Eagle Pharmaceuticals' metabolic inhibitor product; and (4) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

DEADLINE: February 9, 2024 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/eagle-pharmaceuticals-inc-loss-submission-form/?id=64783&from=4

NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of EGRX during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is February 9, 2024. There is no cost or obligation to you to participate in this case.

WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [e-mail]
Phone: [phone]

View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-eagle-pharmaceuticals-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-february-9-2024--nasdaq-egrx-302045260.html

SOURCE The Gross Law Firm

Copyright 2024 PR Newswire